Researchers at Stanford have developed synthetic derivatives of a natural product, azapodophyllotoxin (AZP), that exhibit remarkable anticancer activities.
Researchers at Stanford have developed methods to identify and treat MYC-driven cancers, including renal cell carcinoma (RCC). RCC is a common, aggressive type of kidney cancer and effective therapeutics are lacking.
Researchers at Stanford have developed methods to classify and treat MYC-driven hematopoietic cancers. The MYC oncogene drives the proliferation and survival of many hematopoietic cancers. These cancers are highly aggressive and do not respond to conventional chemotherapies.